JP2024529185A - ラジプロジルの製剤化 - Google Patents

ラジプロジルの製剤化 Download PDF

Info

Publication number
JP2024529185A
JP2024529185A JP2024532367A JP2024532367A JP2024529185A JP 2024529185 A JP2024529185 A JP 2024529185A JP 2024532367 A JP2024532367 A JP 2024532367A JP 2024532367 A JP2024532367 A JP 2024532367A JP 2024529185 A JP2024529185 A JP 2024529185A
Authority
JP
Japan
Prior art keywords
composition
weight
total weight
compound
pharma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024532367A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024529185A5 (cg-RX-API-DMAC7.html
Inventor
ジェニン,マリー
マグリア,ピエランドリア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grin Therapeutics Inc
Original Assignee
Grin Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grin Therapeutics Inc filed Critical Grin Therapeutics Inc
Publication of JP2024529185A publication Critical patent/JP2024529185A/ja
Publication of JP2024529185A5 publication Critical patent/JP2024529185A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024532367A 2021-08-06 2022-08-05 ラジプロジルの製剤化 Pending JP2024529185A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163230331P 2021-08-06 2021-08-06
US63/230,331 2021-08-06
PCT/US2022/039543 WO2023014956A1 (en) 2021-08-06 2022-08-05 Formulations of radiprodil

Publications (2)

Publication Number Publication Date
JP2024529185A true JP2024529185A (ja) 2024-08-01
JP2024529185A5 JP2024529185A5 (cg-RX-API-DMAC7.html) 2025-08-14

Family

ID=83189017

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532367A Pending JP2024529185A (ja) 2021-08-06 2022-08-05 ラジプロジルの製剤化

Country Status (12)

Country Link
US (2) US20250127770A1 (cg-RX-API-DMAC7.html)
EP (1) EP4380547A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024529185A (cg-RX-API-DMAC7.html)
KR (1) KR20240052765A (cg-RX-API-DMAC7.html)
CN (1) CN118019521A (cg-RX-API-DMAC7.html)
AU (1) AU2022323381A1 (cg-RX-API-DMAC7.html)
CA (1) CA3228004A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024002715A2 (cg-RX-API-DMAC7.html)
IL (1) IL310652A (cg-RX-API-DMAC7.html)
MX (1) MX2024001744A (cg-RX-API-DMAC7.html)
PE (1) PE20241385A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023014956A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024402343A1 (en) 2023-12-20 2026-06-11 Grin Therapeutics, Inc. Compositions comprising radiprodil and the use of radiprodil in the treatment of epileptic or neurobehavioral disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011527689A (ja) * 2008-07-08 2011-11-04 リヒター ゲデオン エヌワイアールティー. 2−[4−(4−フルオロ−ベンジル)−ピペリジン−1−イル]−2−オキソ−n−(2−オキソ−2,3−ジヒドロ−ベンゾオキサゾール−6−イル)−アセトアミドの結晶形態
JP2012500801A (ja) * 2008-08-21 2012-01-12 リヒター ゲデオン ニルバーノシャン ミーケデーレスベニュタールシャシャーグ Cns疾患の治療法
JP2012519680A (ja) * 2009-03-03 2012-08-30 リヒター ゲデオン ニルバーノシャン ミーケデーレスベニュタールシャシャーグ ジヒドロベンゾオキサゾール−6−イル−アセトアミド誘導体の新規結晶性水和物、非晶質体、多形体およびその調製プロセス

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100890676B1 (ko) 2001-07-24 2009-03-26 리히데 게데온 베기에스제티 기아르 알티 신규한 카르복시산 아미드 화합물
US8328687B2 (en) 2010-07-09 2012-12-11 Ford Global Technologies, Llc Method for controlling an engine that may be automatically stopped

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011527689A (ja) * 2008-07-08 2011-11-04 リヒター ゲデオン エヌワイアールティー. 2−[4−(4−フルオロ−ベンジル)−ピペリジン−1−イル]−2−オキソ−n−(2−オキソ−2,3−ジヒドロ−ベンゾオキサゾール−6−イル)−アセトアミドの結晶形態
JP2012500801A (ja) * 2008-08-21 2012-01-12 リヒター ゲデオン ニルバーノシャン ミーケデーレスベニュタールシャシャーグ Cns疾患の治療法
JP2012519680A (ja) * 2009-03-03 2012-08-30 リヒター ゲデオン ニルバーノシャン ミーケデーレスベニュタールシャシャーグ ジヒドロベンゾオキサゾール−6−イル−アセトアミド誘導体の新規結晶性水和物、非晶質体、多形体およびその調製プロセス

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, vol. 7, no. 3, JPN6026030090, 2020, pages 343 - 352, ISSN: 0005913237 *
PHARMACOLOGY RESEARCH & PERSPECTIVES, vol. 7, no. 1, JPN6026030091, 2019, pages 00459, ISSN: 0005913238 *

Also Published As

Publication number Publication date
KR20240052765A (ko) 2024-04-23
CN118019521A (zh) 2024-05-10
CO2024002715A2 (es) 2024-05-20
IL310652A (en) 2024-04-01
CA3228004A1 (en) 2023-02-09
PE20241385A1 (es) 2024-07-09
US20260053786A1 (en) 2026-02-26
AU2022323381A1 (en) 2024-03-21
WO2023014956A9 (en) 2023-12-14
EP4380547A1 (en) 2024-06-12
MX2024001744A (es) 2024-04-23
WO2023014956A1 (en) 2023-02-09
US20250127770A1 (en) 2025-04-24

Similar Documents

Publication Publication Date Title
EP1478399B1 (en) Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
EP1511481B1 (en) Ophthalmological use of roflumilast for the treatment of diseases of the eye
US20070264330A1 (en) Pharmaceutical formulations of pimavanserin
TW201418245A (zh) 醫藥組合物
US20170112798A1 (en) Stabilized pediatric suspension of carisbamate
US20230390230A1 (en) Pharmaceutical composition
US20260053786A1 (en) Formulations of radiprodil
EP3302477B1 (en) Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
EP2563340A2 (en) Water soluble pharmaceutical composition
NZ224497A (en) Pharmaceutical composition comprising flunarizine
US12419881B1 (en) Methods of using radiprodil in the treatment of disorders
WO2011139252A2 (en) Efervescent formulations comprising cefdinir
US20200179373A1 (en) Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
US20220071987A1 (en) Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
MX2013012827A (es) Composicion oral liquida que comprende sodio divalproex y proceso para la preparar la misma.
US20200030318A1 (en) Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
WO2016114734A1 (en) Pharmaceutical formulation of trimebutine maleate and simethicone comprising acidifying agent
EP4180042A1 (en) A film coated tablet comprising micronized tofacitinib
CA3238703A1 (en) A film coated tablet comprising micronized tofacitinib
WO2026076270A1 (en) Oral mucosal formulations of aspirin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250805

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250805

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20260410

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260410

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260721